Cell Death Signaling in Cancer Biology and Treatment
Zur Bildergalerie
130,99 €
versandkostenfrei*

inkl. MwSt.
Sofort lieferbar
Bequeme Ratenzahlung möglich!
ab 6,39 € monatlich
65 °P sammeln

    Gebundenes Buch

A key goal in the treatment of cancer is to achieve selective and efficient killing of tumor cells. The aim of Cell Death Signaling in Cancer Biology and Treatment is to describe state-of-the-art approaches and future opportunities for achieving this goal by targeting mechanisms and pathways that regulate cancer cell death. In this book, molecular defects in cell death signaling that characterize cancer cells, including dysregulation of cell death due to overexpression/hyperactivation of oncoproteins, as well as the loss of tumor suppressor proteins will be described. The potential for…mehr

Produktbeschreibung
A key goal in the treatment of cancer is to achieve selective and efficient killing of tumor cells. The aim of Cell Death Signaling in Cancer Biology and Treatment is to describe state-of-the-art approaches and future opportunities for achieving this goal by targeting mechanisms and pathways that regulate cancer cell death. In this book, molecular defects in cell death signaling that characterize cancer cells, including dysregulation of cell death due to overexpression/hyperactivation of oncoproteins, as well as the loss of tumor suppressor proteins will be described. The potential for targeting microRNAs will be discussed. Multiple chapters will describe preclinical and clinical approaches that are currently being used to target epigenetic modifications, DNA repair pathways, and protein chaperones, as a means of provoking tumor cell death. Finally, the development and application of novel agents and approaches for targeting specific components of cell death signaling pathways and machinery will be reviewed. Defects in cell death pathways promote tumor development and progression, with potentially devastating consequences for cancer patients. Greater understanding of the defects occurring in cancer cells, and the unique characteristics of tumors which can make them vulnerable to cell death stimuli, offers tremendous opportunities for developing novel and effective anti-cancer therapies. In Cell Death in Cancer Biology and Treatment leading experts in the field provide a wealth of up-to-date knowledge regarding the molecular mechanisms and cell biological processes that control cell death. Each chapter also highlights recent advances in the translation of basic research findings into clinical trials. Beginning and established investigators alike will benefit from the thorough presentations of the most promising avenues for future development of cell death-based, anti-cancer strategies and agents. The volume begins with a detailed description of many of the cell death defects that have been identified in human tumor specimens. The unique bioenergetics of cancer cells, and the influence of the tumor microenvironment, autophagy, and cellular microRNAs on cancer cell death are then discussed, along with current progress in targeting these distinctive features and processes. Additional chapters describe recent advances, and the therapeutic benefits of targeting DNA repair pathways, protein chaperones, sphingolipid signaling, Bcl-2 family members, IAPs, death receptor signaling, the proteasome, and survival signaling emanating from the PI3K/AKT and RAS/RAF/MEK/ERK pathways. Finally, recent discoveries are presented regarding interactions between the immune system and dying cancer cells and the potential for optimizing these interactions to maximize anti-cancer activities. In summary, Cell Death in Cancer Biology and Treatment will be a valuable resource for scientists interested in cutting-edge understanding of aberrant cell death in cancer cells, and the multitude of innovative molecular targeting approaches that are actively being pursued to achieve selective activation of cell death in human malignancies.
  • Produktdetails
  • Cell Death in Biology and Diseases Vol.1
  • Verlag: Springer, Berlin; Humana Press
  • Artikelnr. des Verlages: 80113377
  • Erscheinungstermin: Januar 2013
  • Englisch
  • Abmessung: 244mm x 159mm x 30mm
  • Gewicht: 756g
  • ISBN-13: 9781461458463
  • ISBN-10: 1461458463
  • Artikelnr.: 36350906
Autorenporträt
Dr. Daniel E. Johnson received his undergraduate training at North Park University and his doctoral degree in molecular biology from Princeton University.  He was a postdoctoral fellow at the University of California San Francisco.  In 1993 he joined the faculty at the University of Pittsburgh and the University of Pittsburgh Cancer Institute, where he is currently a Professor in the Departments of Medicine and Pharmacology & Chemical Biology.  Dr. Johnson has served as a standing member on study sections for the National Institutes of Health and American Cancer Society, and is a long-standing Section Editor for the journal Leukemia.  His research has focused on molecular mechanisms of apoptosis in leukemia and head and neck cancer, as well as the mechanisms of myeloid differentiation.  He has placed particular emphasis on the translation of findings from his laboratory to the clinic, and together with physician scientist collaborators has helped develop ongoing trials in both acute myeloid leukemia and head and neck cancer. 
Inhaltsangabe
Defective Apoptosis Signaling in Cancer.- The Warburg Effect and Beyond: Metabolic Dependencies for Cancer Cells.- Emerging Opportunities for Targeting the Tumor-Stroma Interactions for Increasing the Efficacy of Chemotherapy.- The Role of Autophagy in Drug Resistance and Potential for Therapeutic Targeting.- microRNAs in Cell Death and Cancer.- Targeting DNA Repair Pathways for Cancer Therapy.- Molecular Chaperones and How Addiction Matters in Cancer Therapy.- Sphingolipid Metabolism and Signaling as a Target for Cancer Treatment.- Leading Small Molecule Inhibitors of Anti-apoptotic Bcl-2 Family Members.- SMAC IAP Addiction in Cancer.- Harnessing Death Receptor Signaling for Cancer Treatment.- Proteasome Inhibition as a Novel Strategy for Cancer Treatment.- New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways.- Activation of Immune-Mediated Tumor Cell Death by Chemotherapy.